Literature DB >> 24591208

Aminopeptidase activities as prospective urinary biomarkers for bladder cancer.

Jennifer M Taylor1, Mariana Yaneva, Kevin Velasco, John Philip, Hediye Erdjument-Bromage, Irina Ostrovnaya, Hans G Lilja, Bernard H Bochner, Paul Tempst.   

Abstract

PURPOSE: Proteases have been implicated in cancer progression and invasiveness. We have investigated the activities, as opposed to simple protein levels, of selected aminopeptidases in urine specimens to serve as potential novel biomarkers for urothelial cancer. EXPERIMENTAL
DESIGN: The unique urinary proteomes of males and females were profiled to establish the presence of a gender-independent set of aminopeptidases. Samples were also collected from patients with urothelial cancer and matched controls. A SOP for urine processing was developed taking into account hydration variation. Five specific aminopeptidase activity assays, using fluorophoric substrates, were optimized for evaluation of marker potential.
RESULTS: Nineteen exopeptidases and 21 other proteases were identified in urine and the top-five most abundant aminopeptidases, identical in both genders, selected for functional studies. Depending on the enzyme, activities were consistently lower (p ≤ 0.05), higher or unchanged in the cancer samples as compared to controls. Two selected aminopeptidase activities used as a binary classifier resulted in a ROC curve with an AUC = 0.898. CONCLUSION AND CLINICAL RELEVANCE: We have developed functional assays that characterize aminopeptidase activities in urine specimens with adequate technical and intraindividual reproducibility. With further testing, it could yield a reliable biomarker test for bladder cancer detection or prognostication.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Activity biomarkers; Aminopeptidases; Bladder cancer; Fluorescence; Urine

Mesh:

Substances:

Year:  2014        PMID: 24591208      PMCID: PMC4059539          DOI: 10.1002/prca.201300118

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  42 in total

Review 1.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility.

Authors:  Nader Rifai; Michael A Gillette; Steven A Carr
Journal:  Nat Biotechnol       Date:  2006-08       Impact factor: 54.908

Review 2.  Discovery of urinary biomarkers.

Authors:  Trairak Pisitkun; Rose Johnstone; Mark A Knepper
Journal:  Mol Cell Proteomics       Date:  2006-07-12       Impact factor: 5.911

Review 3.  Defining optimal therapy for muscle invasive bladder cancer.

Authors:  Harry W Herr; Zohar Dotan; S Machele Donat; Dean F Bajorin
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

4.  Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.

Authors:  H Barton Grossman; Mark Soloway; Edward Messing; Giora Katz; Barry Stein; Vahan Kassabian; Yu Shen
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

5.  Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age.

Authors:  Josep Villanueva; Andrew J Martorella; Kevin Lawlor; John Philip; Martin Fleisher; Richard J Robbins; Paul Tempst
Journal:  Mol Cell Proteomics       Date:  2006-08-08       Impact factor: 5.911

6.  Dipeptidyl-peptidase IV from rat liver.

Authors:  Y Ikehara; S Ogata; Y Misumi
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

7.  Secretoglobin 2A1 is under selective androgen control mediated by a peculiar binding site for Sp family transcription factors.

Authors:  Fei Xiao; Andreas Mirwald; Maria Papaioannou; Aria Baniahmad; Jörg Klug
Journal:  Mol Endocrinol       Date:  2005-07-14

8.  Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase.

Authors:  H J Dubbink; N S Verkaik; P W Faber; J Trapman; F H Schröder; J C Romijn
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

9.  UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing.

Authors:  Tine Hajdinjak
Journal:  Urol Oncol       Date:  2008-01-15       Impact factor: 3.498

10.  Increased APN/CD13 and acid aminopeptidase activities in head and neck squamous cell carcinoma.

Authors:  Itxaro Pérez; Adolfo Varona; Lorena Blanco; Javier Gil; Francisco Santaolalla; Aitor Zabala; Agustin Martínez Ibarguen; Jon Irazusta; Gorka Larrinaga
Journal:  Head Neck       Date:  2009-10       Impact factor: 3.147

View more
  4 in total

1.  Portable bioluminescent platform for in vivo monitoring of biological processes in non-transgenic animals.

Authors:  Aleksey Yevtodiyenko; Arkadiy Bazhin; Pavlo Khodakivskyi; Aurelien Godinat; Ghyslain Budin; Tamara Maric; Giorgio Pietramaggiori; Sandra S Scherer; Marina Kunchulia; George Eppeldauer; Sergey V Polyakov; Kevin P Francis; Jeffrey N Bryan; Elena A Goun
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

Review 2.  Ten Years of Proteomics in Bladder Cancer: Progress and Future Directions.

Authors:  Maria Frantzi; Antonia Vlahou
Journal:  Bladder Cancer       Date:  2017-01-27

3.  Giant magnetoresistive biosensors for real-time quantitative detection of protease activity.

Authors:  Sandeep Adem; Sonal Jain; Michael Sveiven; Xiahan Zhou; Anthony J O'Donoghue; Drew A Hall
Journal:  Sci Rep       Date:  2020-05-14       Impact factor: 4.379

Review 4.  New directions of activity-based sensing for in vivo NIR imaging.

Authors:  Amanda K East; Melissa Y Lucero; Jefferson Chan
Journal:  Chem Sci       Date:  2020-07-03       Impact factor: 9.825

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.